Milrinone
Milrinone
Milrinone is a phosphodiesterase 3 inhibitor used primarily in the treatment of heart failure. On January 8, 2018, the United States Food and Drug Administration (FDA) designated Milrinone as an orphan drug for the treatment of right heart failure (RHF) in patients with left ventricular assist devices (LVADs). This designation highlights the drug's importance in treating a condition affecting a relatively small patient population, underscoring the commitment to advancing care for individuals with severe cardiac conditions. The Baker Heart and Diabetes Institute, known for its research and development in heart and diabetes care, manufactures and distributes Milrinone.
Pharmacology
Milrinone works by inhibiting phosphodiesterase 3 (PDE3), which increases cyclic adenosine monophosphate (cAMP) in heart muscle cells. This action leads to improved myocardial contractility and vasodilation, thereby enhancing cardiac output and reducing the symptoms of heart failure.
Therapeutic Uses
While Milrinone is used for the management of acute decompensated heart failure, its role in supporting patients with LVADs, particularly those with right heart failure, is of significant interest. The orphan drug designation by the FDA for this specific use recognizes the critical need for effective therapies in this high-risk patient group.
Administration
Milrinone can be administered intravenously for acute heart failure management, offering rapid onset of action. Its use in LVAD patients requires careful monitoring by healthcare professionals to optimize dosages and manage potential side effects effectively.
Side Effects
Common side effects associated with Milrinone include:
- Arrhythmias
- Hypotension
- Headaches
- Nausea
Development and Distribution
The Baker Heart and Diabetes Institute, with its focus on cardiovascular diseases and diabetes, oversees the development and distribution of Milrinone. The institute's involvement ensures that the drug is produced according to high-quality standards and is readily available to those in need.
See Also
External Links
 | |
|---|---|
 |
 |
Resources
| Additional resources | ||
|---|---|---|
|
Milrinone
|
<html><link rel="canonical" href="https://wikimd.com/wiki/Milrinone">
<meta name=”viewport” content=”width=device-width, initial-scale=1″>
</html>
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
